<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041325</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 1831</org_study_id>
    <nct_id>NCT02041325</nct_id>
  </id_info>
  <brief_title>Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias</brief_title>
  <official_title>Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston VA Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston VA Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to determine if the study drug lenalidomide will increase the body's
      immune response, which is the body's response against infections or tumors, to hepatitis B
      vaccine in patients with plasma cell diseases which include multiple myeloma, monoclonal
      gammopathy of unknown significance (MGUS) and Waldenstr√∂m's Macroglobulinemia. It is not a
      study to see if lenalidomide is an effective treatment for plasma cell disease.

      Participants in this study have multiple myeloma or other plasma cell disease and have never
      been vaccinated with hepatitis B vaccine. One of the effects of the drug lenalidomide is to
      alter the immune system and thereby increase immune response. It also has some effect against
      cancer cells; therefore, in theory, it may reduce or prevent the growth of cancer cells.

      In this study, one-half of the subjects will be chosen at random to receive the study drug
      and the other half will take a placebo pill (a sugar pill that looks the same as the real
      medication). This is a double blind study where neither the subjects nor the investigators
      know whether the patient receives the study drugs or placebo pills. The effects of the active
      drug lenalidomide will be compared to the effects of the placebo. The results from this study
      will be also be compared with a similar but separate study to be done on individuals without
      known disease.

      This study expects to enroll 64 subjects and will be carried out at the Boston VA Healthcare
      System and the Dana Farber Cancer Institute.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary object of this study is to evaluate the effect of CC-5013 on the response to
      hepatitis B vaccine in myeloma. Secondary objectives include the evaluation of immunologic
      and functional genomic changes following CC-55013.

      This study will be a two-center, randomized, double-blinded, placebo-controlled trial. A
      single dose of Hepatitis B vaccine will be administered to subjects. CC-5013 or placebo will
      be administered for 7 days prior to and 7 days after the vaccine. Collection of samples for
      immune analysis will be performed prior to the initiation of CC-5013 administration, at the
      time of vaccination, and 7, 14, and 28 days after vaccination. Safety assessment will be
      performed at each visit.

      Primary Endpoint

        -  Titer of antibodies to hepatitis B virus Secondary Endpoints

        -  Immune analysis

        -  Hepatitis B related T cell response

        -  Safety profile

      All the patients should not have a prior response against hepatitis B surface antigen. The
      study will be comprised of 64 multiple myeloma patients who have not taken any therapeutic
      agents in the 30 days prior to enrollment in the study. Subjects will be randomly assigned to
      receive or not receive CC-5013, and all will be vaccinated. The study is designed to detect a
      biological difference of 50% with an alpha of 0.05 and a beta of 0.8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive for Hepatitis B Surface Antigen</measure>
    <time_frame>6 weeks</time_frame>
    <description>The number of participants who test positive for the antibody titer against hepatitis B surface antigen (HbSAg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of Subjects With a T-cell Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>Participants who displayed a T cell responses against HbSAg following vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypic Changes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Phenotypic changes in peripheral blood cells following CC-5013 (lenalidomide) administration especially in regards to CD3, CD4, CD8 T cells, and NK and NKT cells.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Plasma Cell Disorder</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form.

          -  Age &gt; = 18 years at the time of signing the informed consent form.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Must have confirmed diagnosis of plasma cell disorder.

          -  Patients with prior thalidomide or CC-5013 (lenalidomide) use are eligible but these
             agents must have been discontinued at least 4 weeks prior to treatment in this study.

          -  All previous cancer therapy, including chemotherapy, and dexamethsone must have been
             discontinued at least 4 weeks prior to treatment in this study. Patients with recent
             radiation, hormonal therapy and surgery are eligible.

          -  Patients must not have received prior Hepatitis B vaccination.

          -  Patient should be negative for antibody against HbSAg.

          -  ANC &gt;= 1000, Platelets &gt;= 75,000.

          -  Women of childbearing potential (WCBP) must have a negative urine pregnancy test at
             screening (Visit 1). In addition, sexually active WCBP must agree to use two of the
             following adequate forms of contraception throughout the entire study (tubal ligation;
             intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).
             A WCBP must agree to have pregnancy tests 4 weeks after her last dose of lenalidomide.
             Due to the short duration of drug therapy, abstinence would also be a reasonable
             option.

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Pregnant or lactating females.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          -  Use of any other experimental drug or therapy within 28 days of baseline.

          -  Known hypersensitivity to thalidomide.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          -  Concurrent use of other anti-cancer agents or treatments.

          -  Known HIV, HBV and HCV positivity.

          -  Clinically significant autoimmune disease.

          -  Serious intercurrent illness such as active infection requiring IV antibiotics,
             significant cardiac or pulmonary disease.

          -  Psychiatric disorder, alcohol or illicit drug use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil C Munshi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Boston Healthcare System; Harvard Medical School; Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Boston Healthcare System</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <results_first_submitted>February 9, 2016</results_first_submitted>
  <results_first_submitted_qc>April 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 17, 2016</results_first_posted>
  <last_update_submitted>April 10, 2016</last_update_submitted>
  <last_update_submitted_qc>April 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston VA Research Institute, Inc.</investigator_affiliation>
    <investigator_full_name>Nikhil Munshi, M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Medicine Harvard Medical School; Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide</title>
          <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide</title>
          <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" lower_limit="46" upper_limit="90"/>
                    <measurement group_id="B2" value="67.5" lower_limit="47" upper_limit="78"/>
                    <measurement group_id="B3" value="72.3" lower_limit="46" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Positive for Hepatitis B Surface Antigen</title>
        <description>The number of participants who test positive for the antibody titer against hepatitis B surface antigen (HbSAg).</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd or placebo for 2 weeks.
Lenalidomide: Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd or placebo for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered for 7 days prior to and 7 days after the vaccine.
Placebo: Placebo will be administered for 7 days prior to and 7 days after the vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive for Hepatitis B Surface Antigen</title>
          <description>The number of participants who test positive for the antibody titer against hepatitis B surface antigen (HbSAg).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Number of participants with adverse events as a measure of safety and tolerability</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Number of participants with adverse events as a measure of safety and tolerability</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantity of Subjects With a T-cell Response</title>
        <description>Participants who displayed a T cell responses against HbSAg following vaccination</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
Lenalidomide: Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
Placebo: Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantity of Subjects With a T-cell Response</title>
          <description>Participants who displayed a T cell responses against HbSAg following vaccination</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phenotypic Changes</title>
        <description>Phenotypic changes in peripheral blood cells following CC-5013 (lenalidomide) administration especially in regards to CD3, CD4, CD8 T cells, and NK and NKT cells.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Phenotypic Changes</title>
          <description>Phenotypic changes in peripheral blood cells following CC-5013 (lenalidomide) administration especially in regards to CD3, CD4, CD8 T cells, and NK and NKT cells.</description>
          <units>cells/cmm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total T cells CD3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="851.5" lower_limit="630" upper_limit="1570"/>
                    <measurement group_id="O2" value="715" lower_limit="531" upper_limit="1834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helper T cells CD3+/CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="591" lower_limit="388" upper_limit="1094"/>
                    <measurement group_id="O2" value="525" lower_limit="316" upper_limit="1055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytotoxic T cells CD3+/CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296" lower_limit="77" upper_limit="528"/>
                    <measurement group_id="O2" value="183" lower_limit="117" upper_limit="1243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Natural Killer cells CD56+/CD16+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.5" lower_limit="98" upper_limit="662"/>
                    <measurement group_id="O2" value="228" lower_limit="180" upper_limit="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide</title>
          <description>Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infartion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nikhil C. Munshi</name_or_title>
      <organization>BVARI</organization>
      <phone>857-203-6172</phone>
      <email>nikhil_munshi@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

